| 1 |
NCT01827241 |
Recruiting |
Outcome of Colonoscopy Screening and Surveillance |
|
|
Observational |
|
- M.D. Anderson Cancer Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Polyp Detection in Colon Cancer Screening and Surveillance
|
5000 |
All |
18 Years and older (Adult, Senior) |
NCT01827241 |
DR11-0264 |
|
September 2011 |
December 2021 |
December 2021 |
April 9, 2013 |
October 25, 2017 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 2 |
NCT02137668 |
Recruiting |
Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin |
- Primary Sclerosing Cholangitis
- Biliary Atresia
|
|
Interventional |
Phase 1 |
- Sacramento Pediatric Gastroenterology
- Sacramento Pediatric Gastroenterology
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis and Biliary Atresia
|
200 |
All |
up to 40 Years (Child, Adult) |
NCT02137668 |
Davies 1 |
|
July 2010 |
May 2018 |
July 2028 |
May 14, 2014 |
November 15, 2016 |
|
- Sacramento Pediatric Gastroenterology
Sacramento, California, United States
|
| 3 |
NCT03337217 |
Recruiting |
Colonoscopy in the Prone Position for Patients With BMI Greater Than 30 |
|
- Procedure: Position during colonoscopy
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Cecal intubation time measured in seconds
- Milligrams of sedative used for sedation
- Technical difficulty of procedure (questionnaire)
|
150 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT03337217 |
20078 |
|
November 2017 |
November 2018 |
December 2018 |
November 8, 2017 |
November 17, 2017 |
|
- University of Virginia
Charlottesville, Virginia, United States
|
| 4 |
NCT02979509 |
Recruiting |
Evaluation of Diagnostic Yield of EUS-Guided Tissue Sampling |
|
- Other: Endoscopic ultrasound- (EUS) guided tissue sampling
|
Observational |
|
- University of Florida
- Borland Groover Clinic, Jacksonville, FL
- Northwestern University, Chicago, IL
- (and 8 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Overall diagnostic yield of EUS-TS
- Diagnostic Yield of EUS-guided tissue sampling solid lesions
- Diagnostic Yield of EUS-guided tissue sampling cystic lesions
- (and 4 more...)
|
300 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT02979509 |
IRB201600783 |
|
June 2016 |
June 2020 |
August 2020 |
December 1, 2016 |
December 8, 2017 |
|
- University of Florida
Gainesville, Florida, United States
|
| 5 |
NCT02661750 |
Recruiting |
Safety and Efficacy of High Dose Bowel Preparation Solutions for Patients With Difficult To Clean Colons For Colonoscopy |
- Preparation for Colonoscopy
|
|
Observational |
|
- Gastroenterology Services, Ltd.
- Gastroenterology Services, Ltd.
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Bowel Cleanliness
- Patient tolerance
- Electrolyte changes
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT02661750 |
2015-0004-02 |
|
January 2016 |
January 2019 |
January 2019 |
January 22, 2016 |
March 24, 2017 |
|
- Gastroenterology Services
Downers Grove, Illinois, United States
|
| 6 |
NCT03425097 |
Recruiting |
Fexofenadine Use in Gastroesophageal Reflux Disease |
|
- Drug: Fexofenadine
- Drug: Placebo - Cap
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Mean percentage of reflux free days
- Mean number of reflux episodes per day
- Mean GERD-HRQL questionnaire score
- (and 4 more...)
|
40 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT03425097 |
IRB-44650 |
|
February 7, 2018 |
March 2019 |
May 2019 |
February 7, 2018 |
February 9, 2018 |
|
- Silicon Valley Gastroenterology 2490 Hospital Dr. Suite 211
Mountain View, California, United States
|
| 7 |
NCT03209349 |
Recruiting |
Investigation of Cecal Intubation Rates and Pain Levels Between Water Exchange and Air Insufflation Flexible Sigmoidoscopy |
|
- Procedure: Water Exchange Sigmoidoscopy
- Procedure: Air Insufflation Sigmoidoscopy
|
Interventional |
Not Applicable |
- Kelowna Gastroenterology Associates
- Veteran Affairs Sepulveda Ambulatory Care Cente
- Kelowna Gastroenterology Associates
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Screening
|
- Full colon exam
- Recalled Discomfort
- Adenoma detection rates
|
200 |
All |
50 Years to 74 Years (Adult, Senior) |
NCT03209349 |
2016-17-078-I |
|
June 14, 2017 |
December 8, 2019 |
December 9, 2019 |
July 6, 2017 |
March 9, 2018 |
|
- Sepulveda Ambulatory Care Center
North Hills, California, United States - Kelowna General Hospital
Kelowna, British Columbia, Canada
|
| 8 |
NCT03410524 |
Recruiting |
Evaluation of Oral Simethicone With Low Volume Polyethylene Glycol Bowel Preparation During Colonoscopy |
|
- Drug: Simethicone Solution
- Drug: Water
|
Interventional |
Phase 3 |
- University of Nevada, Reno
- Gastroenterology Consultants
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Diagnostic
|
- Intraluminal Bubbles Scale
- Boston Bowel Preparation Scale
- Cecal insertion time
- (and 6 more...)
|
250 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03410524 |
1139179 |
|
January 9, 2018 |
October 31, 2018 |
December 31, 2018 |
January 25, 2018 |
January 25, 2018 |
|
- Gastroenterology Consultants Reno - North Office and Endoscopy Center
Reno, Nevada, United States - Gastroenterology Consultants Reno - South Meadows Office and Endoscopy Center
Reno, Nevada, United States
|
| 9 |
NCT03495141 |
Recruiting
New |
Outcomes in Simulated Endoscopy Training |
- Impact of Supervision on Endoscopy Simulation Curriculum
|
- Behavioral: Supervision/Coaching
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Other
|
- Percentage of mucosa inspected
- Time to reach cecum
- Participant satisfaction score
|
35 |
All |
Child, Adult, Senior |
NCT03495141 |
8244 |
|
March 6, 2018 |
July 31, 2019 |
July 31, 2020 |
April 11, 2018 |
April 11, 2018 |
|
- University of Oklahoma
Oklahoma City, Oklahoma, United States
|
| 10 |
NCT02196935 |
Recruiting |
Los Angeles Prospective GI Biliary and EUS Series |
- Biliary Disease
- Pancreatitis
- Gastrointestinal Neoplasms
|
|
Observational |
|
- University of Southern California
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Successful ERCP or EUS
- Bile Duct Stone
- Length of Hospitalization
- Definitive Diagnosis
|
2500 |
All |
Child, Adult, Senior |
NCT02196935 |
HS-10-00369 |
|
September 2010 |
December 2018 |
December 2018 |
July 22, 2014 |
April 20, 2017 |
|
- Los Angeles County Hospital
Los Angeles, California, United States
|
| 11 |
NCT02412553 |
Recruiting |
Dietary Therapy and Gut Microbiome in Crohn's Disease and Ulcerative Colitis |
|
- Other: Specific carbohydrate diet
- Other: Elemental diet
|
Interventional |
Not Applicable |
- Massachusetts General Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical remission
- Clinical response
- Biochemical response - CRP
- Biochemical response - fecal calprotectin
|
40 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT02412553 |
2014P001134 |
|
October 2014 |
October 2018 |
October 2018 |
April 9, 2015 |
March 22, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 12 |
NCT02530216 |
Recruiting |
Evaluating the Impact of Automated Evaluation of Gastrointestinal Symptoms (AEGIS) on Clinical Outcomes |
- Abdominal Pain
- Deglutition Disorders
- Fecal Incontinence
- (and 4 more...)
|
- Other: AEGIS (Automated Evaluation of Gastrointestinal Symptoms)
|
Interventional |
Not Applicable |
- Cedars-Sinai Medical Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Prevalence of documented alarm symptoms
- Prevalence of diagnosed organic disease
- Time to diagnosis of organic disease
|
448 |
All |
18 Years and older (Adult, Senior) |
NCT02530216 |
Pro00045243 |
AEGIS |
April 10, 2017 |
June 2018 |
December 2018 |
August 20, 2015 |
January 26, 2018 |
|
- Cedars-Sinai Medical Center
Los Angeles, California, United States
|
| 13 |
NCT02775045 |
Recruiting |
Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis |
|
- Other: Observation Period
|
Observational |
|
- University of Wisconsin, Madison
- National Institutes of Health (NIH)
- National Institute of Allergy and Infectious Diseases (NIAID)
|
Other / NIH |
- Observational Model: Other
- Time Perspective: Prospective
|
- Eosinophil Esophagitis symptom score
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT02775045 |
2016-0508
R21AI122103-01A1 |
EoE |
August 30, 2016 |
May 2018 |
May 2018 |
May 17, 2016 |
October 17, 2017 |
|
- UW Madison School of Medicine and Public Health
Madison, Wisconsin, United States
|
| 14 |
NCT00892593 |
Recruiting |
Augmentation of Screening Colonoscopy With Fecal Immunochemical Testing |
|
- Device: Fecal Immunochemical Testing
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- rate of significant colon neoplasia among those who enter a screening or surveillance program with FIT testing added at yearly intervals vs. that of "usual care" patients in the same patient population.
- the pathology found at repeat colonoscopy in each group.
|
4100 |
All |
18 Years and older (Adult, Senior) |
NCT00892593 |
ASC-FIT |
ASC-FIT |
May 2009 |
May 2019 |
May 2020 |
May 4, 2009 |
July 21, 2014 |
|
- Digestive Health Specialists, PA
Winston Salem, North Carolina, United States - Piedmont Gastroenterology Specialists, PA
Winston Salem, North Carolina, United States - Salem Gastroenterology Associates, PA
Winston Salem, North Carolina, United States
|
| 15 |
NCT01639924 |
Recruiting |
Evaluation of People With Gastrointestinal Disease |
- Gastrointestinal Diseases
|
|
Observational |
|
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Evaluate patients with gastrointestinal disorders.
- During a clinically indicated standard of care test or procedure, allow for donation of extra stool, urine, blood, gastric aspirate or gastrointestinal tissue sample for collection and storage.
- Allow outpatient evaluation and follow-up of patients with a variety of gastrointestinal diseases for the purposes of physician education in the NIDDK accredited gastroenterology training program.
|
999999 |
All |
18 Years and older (Adult, Senior) |
NCT01639924 |
120154
12-DK-0154 |
|
June 18, 2012 |
|
|
July 13, 2012 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 16 |
NCT01412372 |
Recruiting |
The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study |
|
- Drug: Mesalamine
- Drug: Placebo
|
Interventional |
Phase 3 |
- University of Utah
- Shire Human Genetic Therapies, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline in gastrointestinal symptoms and IBS specific quality of life after an 8 week treatment period
|
68 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01412372 |
39402 |
Mesalamine |
June 2010 |
September 2018 |
September 2018 |
August 9, 2011 |
January 4, 2018 |
|
- University of Utah
Salt Lake City, Utah, United States
|
| 17 |
NCT02614703 |
Recruiting |
"Acetic Acid Chromoendoscopy in Barrett's Esophagus Surveillance |
|
- Drug: Chromoendoscopy using Acetic Acid 2.5%
- Other: Standard random esophageal biopsies
|
Interventional |
Phase 2
Phase 3 |
- Doctors Hospital at Renaissance
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- Total number of subjects with neoplasia when using acetic acid chromoendoscopy versus standardized random biopsies.
|
185 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT02614703 |
0000001 |
|
March 10, 2017 |
September 13, 2018 |
December 13, 2018 |
November 25, 2015 |
March 14, 2017 |
|
- Doctors Hospital at Renaissance/Endoscopy Department
Edinburg, Texas, United States
|
| 18 |
NCT03078530 |
Recruiting |
Probiotic (Visbiome) for Gulf War Illness |
|
- Drug: Placebo
- Drug: Visbiome
- Drug: VSL#3
|
Interventional |
Phase 2
Phase 3 |
- Ashok Tuteja
- United States Department of Defense
- VA Salt Lake City Health Care System
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in the bowel symptom scale from the baseline
- Change in chronic fatigue (1-5 scale) from baseline
|
60 |
All |
35 Years to 75 Years (Adult, Senior) |
NCT03078530 |
IRB_00059006 |
|
September 13, 2013 |
May 31, 2018 |
May 31, 2018 |
March 13, 2017 |
December 13, 2017 |
|
- George E Wahlen VA Medical Center
Salt Lake City, Utah, United States
|
| 19 |
NCT02881944 |
Recruiting |
Effect of Diet on Gulf War Illness |
|
- Behavioral: Low FODMAP Diet
- Behavioral: High FODMAP Diet
|
Interventional |
Not Applicable |
- Ashok Tuteja
- United States Department of Defense
- VA Salt Lake City Health Care System
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in self-reported global Bowel Symptom Score
- Change in self-reported Irritable Bowel Syndrome Quality of Life (IBS-QOL) score
|
68 |
All |
25 Years to 90 Years (Adult, Senior) |
NCT02881944 |
IRB_00087668 |
|
August 2016 |
September 2018 |
September 2018 |
August 29, 2016 |
February 1, 2018 |
|
- George E Wahlen VA Medical Center
Salt Lake City, Utah, United States
|
| 20 |
NCT03006809 |
Recruiting |
Optimal Fecal Microbiota Transplant Dosing for Mild to Moderate Ulcerative Colitis |
|
- Biological: Fecal Microbiota Transplantation (FMT), OpenBiome
- Other: pretreatment antibiotics
|
Interventional |
Phase 1 |
- Najwa Elnachef
- University of California, San Francisco
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The occurrence of a Serious Adverse event (SAE), solicited and unsolicited AE, new gastrointestinal medical condition and diagnoses from FMT treatment or new infection from FMT treatment
- Steroid-free Clinical Remission at week 9 + endoscopic remission or response defined as total Mayo score ≤ 2 with all four sub-scores ≤ 1 and a ≥ 1 point reduction in endoscopy sub-score
- Changes in microbiome with FMT therapy. Changes in the microbiome: assessed by frequent stool sampling for 16S rRNA analysis prior to each FMT therapy and after the last capsule/enema dose
- (and 8 more...)
|
40 |
All |
18 Years to 64 Years (Adult) |
NCT03006809 |
16-20066 |
|
March 2, 2017 |
December 2018 |
December 2018 |
December 30, 2016 |
October 26, 2017 |
|
- UCSF Division of Gastroenterology at Mount Zion
San Francisco, California, United States
|
| 21 |
NCT03494088 |
Recruiting
New |
Mycobiome Evaluation in Children With Autism & GI Symptoms |
- Autism
- Gastrointenstinal Symptoms
|
|
Observational |
|
- The University of Texas Health Science Center, Houston
- Baylor College of Medicine
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Fecal Mycobiome Composition as assessed by sequencing of fecal fungal species
- Presence of fungal species Candida tropicalis
- Presence of fungal species Candida albicans
- (and 7 more...)
|
60 |
All |
4 Years to 16 Years (Child) |
NCT03494088 |
HSC-MS-17-1015 |
|
March 22, 2018 |
May 1, 2019 |
May 1, 2019 |
April 11, 2018 |
April 11, 2018 |
|
- The University of Texas Health Science Center at Houston
Houston, Texas, United States
|
| 22 |
NCT03270722 |
Recruiting |
Functional Luminal Imaging Probe (FLIP) Topography Use in Patients With Scleroderma and Trouble Swallowing |
- Scleroderma
- Dysphagia
- GERD - Gastro-Esophageal Reflux Disease
|
- Device: FLIP topography
- Procedure: Upper Endoscopy
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- FLIP topography pattern
- Change in medical management
|
60 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT03270722 |
IRB-42435 |
|
January 1, 2018 |
May 2019 |
May 2019 |
September 1, 2017 |
January 29, 2018 |
|
- Stanford Healthcare
Stanford, California, United States
|
| 23 |
NCT02788591 |
Recruiting |
Confocal Endomicroscopy for Non-Erosive Reflux Disease Detection |
- Non-erosive Reflux Disease
- Gastroesophageal Reflux
|
- Drug: Proton Pump Inhibitor (PPI) Therapy
- Drug: Sucralfate
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Evaluate non erosive reflux disease (NERD) Symptoms.
- Evaluate the role of probe based endomicroscopy in the diagnosis of NERD by evaluating dilated intercellular spaces, evaluation of IPCL, and quantification of fluorescein leak.
- Compare quality of life in patients with NERD.
- Compare two medications within each NERD study groups as a subgroup analysis.
|
140 |
All |
18 Years and older (Adult, Senior) |
NCT02788591 |
CENERDD |
CENERDD |
August 2015 |
December 2017 |
June 2018 |
June 2, 2016 |
July 29, 2016 |
|
- Ochsner Health System
Kenner, Louisiana, United States
|
| 24 |
NCT03206905 |
Recruiting |
Safety, Tolerability, and Sustained Weight Loss of Endoscopic Sleeve Gastroplasty With Diet Modification and Exercise |
|
- Procedure: Endoscopic Sleeve Gastroplasty
- Behavioral: Diet and Exercise
|
Interventional |
Not Applicable |
- Weill Medical College of Cornell University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Mean Percentage of Total Body Weight Loss
|
34 |
All |
18 Years to 65 Years (Adult) |
NCT03206905 |
1501015803 |
|
April 1, 2017 |
December 31, 2018 |
July 31, 2019 |
July 2, 2017 |
July 2, 2017 |
|
- Weill Cornell Medicine, Division of Gastroenterology & Hepatology
New York, New York, United States
|
| 25 |
NCT03267069 |
Recruiting |
Evaluating Alcohol Use in Alcoholic Liver Disease |
|
|
Observational |
|
- Nicole T Shen
- New York Presbyterian Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- alcohol recidivism assessed by questionnaire
- alcohol recidivism assessed by clinical interview
- alcohol recidivism assessed by urine ethyl glucuronide
- alcohol recidivism assessed by blood
|
160 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03267069 |
1601016922 |
|
November 27, 2016 |
November 1, 2026 |
November 1, 2027 |
August 30, 2017 |
August 30, 2017 |
|
- New York Presbyterian Hospital - Weill Cornell Medicine and Columbia University Medical Center
New York, New York, United States
|
| 26 |
NCT02372136 |
Recruiting |
Optimizing Individual Nutrition in Preterm Very Low Birth Weight Infants |
- Infant, Premature, Diseases
- Infant, Small for Gestational Age
|
- Dietary Supplement: Individualized Nutrition
- Dietary Supplement: Optimized nutrition
|
Interventional |
Not Applicable |
- University of Texas Southwestern Medical Center
- Children's Medical Center Dallas
- The Gerber Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Growth velocity
- Disproportionate growth (increased fat mass)
- Blood pressure
- (and 10 more...)
|
150 |
All |
up to 7 Days (Child) |
NCT02372136 |
STU 102014-056 |
|
January 2016 |
July 2018 |
July 2021 |
February 26, 2015 |
February 14, 2017 |
|
- UT Southwestern Medical Center
Dallas, Texas, United States
|
| 27 |
NCT00777439 |
Recruiting |
Domperidone for Refractory Gastrointestinal Disorders |
|
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Improvement of symptoms for patients with gastrointestinal disorders who have failed or suffered adverse effects from standard medical treatment.
|
75 |
All |
18 Years and older (Adult, Senior) |
NCT00777439 |
GLA102024 |
|
October 2008 |
January 2017 |
January 2018 |
October 22, 2008 |
August 18, 2016 |
|
- Division of Gastroenterology, Hepatology and Nutrition, UPMC Presbyterian Digesive Disorders Center, 3rd Floor, 200 Lothrop Street
Pittsburgh, Pennsylvania, United States
|
| 28 |
NCT03100487 |
Recruiting |
Efficacy of Audio Recorded Guided Imagery vs Deep Breathing Exercises on Functional Gastrointestinal Pain Disorders |
- Abdominal Pain
- Functional Gastrointestinal Disorders
|
- Device: Apple iPod Shuffle
|
Interventional |
Not Applicable |
- Baylor College of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in abdominal pain symptoms
- Improvement in health-related quality of life
- Change in Psychosocial Distress
- Adherence to Intervention
|
58 |
All |
8 Years to 12 Years (Child) |
NCT03100487 |
H-39390 (Imagery) |
|
August 2016 |
August 2018 |
August 2019 |
April 4, 2017 |
April 4, 2017 |
|
- Texas Children's Hospital
Houston, Texas, United States
|
| 29 |
NCT02954159 |
Recruiting |
Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC |
|
- Drug: Tacrolimus
- Drug: Vedolizumab
- Other: Placebo
|
Interventional |
Phase 3 |
- Medical College of Wisconsin
- Takeda
- Bnai Zion Medical Center
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
|
46 |
All |
18 Years to 65 Years (Adult) |
NCT02954159 |
2016-101742 |
COVET |
May 18, 2017 |
May 2019 |
December 2019 |
November 3, 2016 |
July 11, 2017 |
|
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
| 30 |
NCT00727974 |
Recruiting |
Genetic Analysis of Children With Cyclic Vomiting Syndrome (CVS) and Migraines |
|
|
Observational |
|
- Medical College of Wisconsin
- Children's Hospital and Health System Foundation, Wisconsin
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Identify novel genes that contribute to the risk of CVS using genomewide association analysis approach.
- Perform genotype-phenotype correlations between genetic profiles and various phenotypes of CVS (e.g. menstrual, Sato, calendar-tied) and migraine headaches (e.g. with aura, without aura, hemiplegic migraine)
|
880 |
All |
up to 21 Years (Child, Adult) |
NCT00727974 |
08/24
GC 607 |
|
January 2008 |
December 2019 |
December 2019 |
August 5, 2008 |
March 23, 2018 |
|
- Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States
|
| 31 |
NCT02340312 |
Recruiting |
Functional Dyspepsia Microbiome Study |
|
- Procedure: EGD
- Other: Collection of Stool Specimens
|
Observational |
|
- Children's Mercy Hospital Kansas City
- University of Kansas
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Microbiome Analysis
- Inflammatory Cell Density
- Immunohistochemistry (IHC)
- T-scores for the BASC will be collected as part of this study on the Data Collection Form.
|
200 |
All |
8 Years to 17 Years (Child) |
NCT02340312 |
490390 |
|
January 2015 |
January 2020 |
|
January 16, 2015 |
January 16, 2015 |
|
- The Children's Mercy Hospital
Kansas City, Missouri, United States
|
| 32 |
NCT02324699 |
Recruiting |
Corticosteroids With Vedolizumab in Crohn's Disease |
|
- Drug: Prednisone
- Drug: Placebo
- Drug: Vedolizumab
|
Interventional |
Phase 4 |
- Icahn School of Medicine at Mount Sinai
- Takeda
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Crohn's Disease Activity Index (CDAI)
- CDAI
- Change in CDAI
- (and 4 more...)
|
123 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02324699 |
GCO 14-2209 |
|
April 2016 |
June 2018 |
June 2018 |
December 24, 2014 |
June 14, 2017 |
|
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
|
| 33 |
NCT02330211 |
Recruiting |
Fecal Microbiota Transplant (FMT) in Pediatric Active Crohn's Colitis |
- Inflammatory Bowel Diseases
- Crohn Disease
|
- Biological: Fecal Microbiota Transplant
- Biological: Placebo
|
Interventional |
Phase 1
Phase 2 |
- Stacy A. Kahn
- Boston Children’s Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety and tolerability of universal donor FMT compared to placebo: FMT-related adverse events of grade 2 or above
- Improvement Pediatric Crohn's Disease Activity Index (PCDAI) by 12.5 points or more
- Remission of disease
- Identify biomarkers that may confer a clinical response
|
60 |
All |
5 Years to 30 Years (Child, Adult) |
NCT02330211 |
P00014880 |
|
July 17, 2017 |
March 2018 |
August 2018 |
January 1, 2015 |
November 14, 2017 |
|
- Boston Children's Hospital
Boston, Massachusetts, United States
|
| 34 |
NCT03411252 |
Recruiting |
Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study |
|
- Drug: Mirabegron 50 MG
- Drug: Placebo
|
Interventional |
Early Phase 1 |
- Thomas Jefferson University
- Astellas Pharma Inc
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Changes in lower esophageal sphincter pressures
- Eckardt Achalasia Score (EAS)
|
10 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03411252 |
17P.054 |
|
February 15, 2018 |
December 15, 2018 |
December 15, 2018 |
January 26, 2018 |
January 29, 2018 |
|
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
| 35 |
NCT02463305 |
Recruiting |
Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD) |
|
- Drug: Creatine monohydrate
- Other: Placebo
|
Interventional |
Early Phase 1 |
- University of Colorado, Denver
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Improvement in endoscopic assessment of mucosal inflammation in ulcerative colitis.
- Clinical response in ulcerative colitis disease activity.
- Intestinal permeability
- (and 5 more...)
|
12 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02463305 |
13-3054
UL1TR001082 |
|
April 2016 |
December 2019 |
December 2019 |
June 4, 2015 |
October 26, 2017 |
|
- University of Colorado Hospital
Denver, Colorado, United States
|
| 36 |
NCT03420482 |
Recruiting |
Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy |
|
- Drug: Fecal Microbiota Transplant (FMT) oral capsules
- Drug: Placebo oral capsule
|
Interventional |
Phase 2 |
- Massachusetts General Hospital
- Center for Microbiome Informatics and Therapeutics
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Psychometric Hepatic Encephalopathy Score (PHES)
- Adverse events
- Stroop Test
- (and 3 more...)
|
30 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03420482 |
2017P002296 |
|
April 1, 2018 |
March 31, 2019 |
December 31, 2020 |
February 2, 2018 |
March 30, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 37 |
NCT03118973 |
Recruiting |
Evaluation of Efficacy and Safety of Goff Transpancreatic Septotomy vs. Double Wire Technique for Achieving Biliary Access in Technically Challenging ERCPs |
- Biliary Obstruction
- Biliary Stones
|
- Procedure: Goff trans-pancreatic septotomy vs. Double wire technique
|
Interventional |
Not Applicable |
- Subhas Banerjee
- Stanford University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Successful biliary cannulation assessed by fluoroscopic confirmation of biliary cannulation
- Adverse event rates assessed by 6-month follow-up of clinical and laboratory studies
|
500 |
All |
18 Years and older (Adult, Senior) |
NCT03118973 |
38574 |
|
September 27, 2016 |
January 1, 2020 |
January 1, 2020 |
April 18, 2017 |
April 18, 2017 |
|
- Stanford University School of Medicine
Stanford, California, United States
|
| 38 |
NCT03115411 |
Recruiting |
Prospective Evaluation of Winged Biliary Stent Patency in Patients With Benign Biliary Obstruction |
|
- Device: Winged biliary stent (ViaDuct™)
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT03115411 |
IRB 21604 |
|
September 6, 2011 |
April 10, 2018 |
April 10, 2018 |
April 14, 2017 |
April 14, 2017 |
|
- Stanford University School of Medicine
Stanford, California, United States
|
| 39 |
NCT03228758 |
Recruiting |
Anterior Orientation vs Posterior Orientation in Per Oral Endoscopic Myotomy POEM for the Treatment of Achalasia |
|
- Procedure: Per Oral Endoscopic Myotomy
|
Interventional |
Not Applicable |
- Winthrop University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Periprocedural pain requiring the use of narcotics.
- Incidence of Gastrointestinal Reflux Disease (GERD)
|
290 |
All |
18 Years and older (Adult, Senior) |
NCT03228758 |
17008 |
|
July 24, 2017 |
July 2019 |
November 30, 2019 |
July 25, 2017 |
July 28, 2017 |
|
- NYU WInthrop Hospital
Mineola, New York, United States
|
| 40 |
NCT03120325 |
Recruiting |
Vagal Nerve Stimulation for Gastroparesis |
|
- Device: Vagal Nerve Stimulation
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Effect of Vagal Nerve Stimulation on gastroparesis symptoms as measures by the Gastroparesis Cardinal Symptom Index (GCSI) questionnaire.
- Effect of Vagal Nerve Stimulation on the gastric emptying spirulina breath test emptying time
|
45 |
All |
21 Years to 65 Years (Adult) |
NCT03120325 |
39839 |
VNS |
March 1, 2017 |
March 1, 2018 |
July 1, 2018 |
April 19, 2017 |
February 8, 2018 |
|
- Stanford University Medical Center
Palo Alto, California, United States
|
| 41 |
NCT03304626 |
Recruiting |
Budesonide for Liver Transplant Immune Suppression |
- Acute Cellular Graft Rejection
- New Onset Diabetes After Transplant
|
- Drug: Budesonide 3Mg Capsule
|
Interventional |
Phase 2 |
- University of Cincinnati
- American College of Gastroenterology
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rates of Acute Cellular Rejection
- Rate of New Onset Diabetes After Transplant
- Effect of Budesonide on hypothalamic-pituitary-adrenal axis
- Safety of Budesonide
|
20 |
All |
21 Years to 75 Years (Adult, Senior) |
NCT03304626 |
2016-1488 |
|
June 27, 2017 |
December 31, 2018 |
December 31, 2018 |
October 9, 2017 |
October 9, 2017 |
|
- University of Cincinnati Medical Center
Cincinnati, Ohio, United States
|
| 42 |
NCT03407534 |
Recruiting |
Detection of Exocrine Pancreatic Insufficiency in Patients With Diarrhea and Bloating |
- Diarrhea
- Exocrine Pancreatic Insufficiency
- Abdominal Pain
|
|
Observational |
|
- Baylor College of Medicine
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Prevelance of Pancreatic Insufficency among patients that complain of symptoms of diarrhea and bloating
|
200 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03407534 |
H-37932 |
|
November 2015 |
November 2018 |
November 2018 |
January 23, 2018 |
January 23, 2018 |
|
- Baylor College of Medicine
Houston, Texas, United States
|
| 43 |
NCT02736227 |
Recruiting |
Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation |
|
- Drug: Tacrolimus Withdrawal and Everolimus Monotherapy
|
Interventional |
Not Applicable |
- Northwestern University
- Novartis Pharmaceuticals
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Amount of Treg cells and mRNA observed in peripheral blood prior to and during tacrolimus withdrawal plus everolimus treatment.
|
40 |
All |
18 Years to 89 Years (Adult, Senior) |
NCT02736227 |
STU00201794 |
|
March 2016 |
March 2018 |
March 2019 |
April 13, 2016 |
October 11, 2016 |
|
- Northwestern University Comprehensive Transplant Center
Chicago, Illinois, United States
|
| 44 |
NCT02389062 |
Recruiting |
Noninvasive Markers of Gluten Ingestion in Celiac Disease Patients |
- Adult Form of Celiac Disease
|
- Other: Administration of gluten( food /wheat protein) capsules or placebo(cornstarch) capsules and tests for novel markers will be done at intervals.
|
Interventional |
Not Applicable |
- Thomas Jefferson University
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- 1) Change in the patient estimated gluten intake after administration of study pills using the Celiac Dietary Adherence Test (CDAT), to be assessed at the end of follow up week 12
- 2) Change in the Celiac disease symptoms, using the Celiac Symptom Index (CSI) after administration of study pills; to be assessed at the end of follow up week 12
- 3)Change in IgA antibody to tissue transglutaminase (IgA-TTG) levels after administration of study pills, to be assessed at the end of follow up week 12.
- (and 4 more...)
|
36 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02389062 |
14D.389 |
|
February 2015 |
February 2017 |
February 2019 |
March 17, 2015 |
March 17, 2015 |
|
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
| 45 |
NCT03368066 |
Recruiting |
Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients? |
- Adrenal Insufficiency
- Cirrhosis
- Spur Cell Anemia
- Lecithin Acyltransferase Deficiency
|
|
Interventional |
Phase 3 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Cholesterol Esterification Deficiency
- Spur Cell Anemia
- Adrenal Insufficiency
- (and 2 more...)
|
120 |
All |
18 Years to 110 Years (Adult, Senior) |
NCT03368066 |
20212 |
|
December 15, 2017 |
June 30, 2018 |
June 30, 2018 |
December 11, 2017 |
December 13, 2017 |
|
- University of Virginia Health System
Charlottesville, Virginia, United States
|
| 46 |
NCT02543957 |
Recruiting |
Factors Associated With Increased Risk of Bacteremia and Cholangitis in ERCP With Cholangioscopy |
|
- Procedure: Cholangioscopy
|
Observational |
|
- Baylor College of Medicine
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Examine the Incidence of new onset infectious complications
- Examine the incidence of bacteremia in patients undergoing ERCP with cholangioscopy
|
350 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02543957 |
H-37346 |
|
September 2015 |
September 2018 |
December 2018 |
September 9, 2015 |
January 24, 2018 |
|
- Baylor College of Medicine
Houston, Texas, United States
|
| 47 |
NCT02538406 |
Recruiting |
The Utility of Time Segmental Withdrawal During Screening Colonoscopy for Increasing Adenoma Detection Rate. |
- Adenomatous Polyp of Colon
|
- Other: Segmental withdrawal
|
Observational |
|
- Baylor College of Medicine
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Increase in detection rate of adenomas in the right side of the colon
- Sessile Serrated lesion detection rate
|
400 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02538406 |
H-37320 |
|
August 2015 |
October 15, 2018 |
December 15, 2018 |
September 2, 2015 |
January 24, 2018 |
|
- Baylor College of Medicine
Houston, Texas, United States
|
| 48 |
NCT02130622 |
Recruiting |
Study of Promethazine for Treatment of Diabetic Gastroparesis |
|
- Drug: Promethazine
- Drug: Sugar pill
|
Interventional |
Phase 2 |
- Dartmouth-Hitchcock Medical Center
- American College of Gastroenterology
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in patient-reported symptoms as measured by the Gastroparesis Cardinal Symptom Index score (GCSI, 14) from week 0 to week 4.
- Occurrence of adverse events
- Use of rescue medication
- The impact on work activity as measured by the Work Productivity and Activity Impairment Questionnaire. (WPAI).
|
24 |
All |
18 Years to 65 Years (Adult) |
NCT02130622 |
D14076 |
|
July 2014 |
December 2020 |
|
May 5, 2014 |
May 12, 2017 |
|
- Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
|
| 49 |
NCT01774487 |
Recruiting |
Pentoxifylline Therapy in Biliary Atresia |
|
|
Interventional |
Phase 2 |
- Baylor College of Medicine
- Texas Children's Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in serum conjugated bilirubin
- Change in Weight
- Change in serum markers
- (and 2 more...)
|
60 |
All |
up to 180 Days (Child) |
NCT01774487 |
BCM/TCH-H-31387 |
|
January 2013 |
January 2019 |
January 2019 |
January 24, 2013 |
September 14, 2017 |
|
- Texas Children's Hospital and Baylor College of Medicine
Houston, Texas, United States
|
| 50 |
NCT03270085 |
Recruiting |
Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption |
- Chronic Diarrhea
- Irritable Bowel Syndrome With Diarrhea
- Bile Acid Malabsorption
|
- Drug: Colesevelam
- Other: Placebo
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Other
|
- Patients with IBS-D with increased bowel bile acid will be treated with colesevelam to determine if stool frequency and consistency improves via daily bowel diaries.
- Patients with IBS-D with increased bowel bile acid will be treated with colesevelam to determine if stool frequency and consistency improves via fecal bile acids.
|
45 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03270085 |
17-004639 |
|
December 7, 2017 |
July 20, 2018 |
July 20, 2018 |
September 1, 2017 |
December 11, 2017 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
Create an RSS feed from your search for:
Download the search results for: